Datasets:

Haxirus

/

Fine-Tuning_Dataset

like 0

Does Adalimumab and Varicella zoster vaccine (liveattenuated) interact?

In a placebo-controlled clinical trial of patients with RA, no difference was detected in antipneumococcal antibody response between adalimumab and placebo treatment groups when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with adalimumab. Similar proportions of patients developed protective levels of anti-influenza antibodies between adalimumab and placebo treatment groups; however, titers in aggregate to influenza antigens were moderately lower in patients receiving adalimumab. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Varicella zoster vaccine (live/attenuated), and the severity of the interaction is minor.

Does Adalimumab and Varicella zoster vaccine (recombinant) interact?

Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Vedolizumab interact?

Various clinical studies have shown that the use of tumor necrosis factor-alpha (TNF-α) inhibitors in patients is associated with the possibility of developing infections, lymphoma, and/or other malignancies, some incidences of which can be fatal . At the same time, infections likely due to immunosuppression are also one of the most common adverse effects associated with the use of the integrin receptor antagonist, vedolizumab . As a result, if vedolizumab is used concomitantly with TNF-α inhibitors, there is a concern that the combined, additive immunosuppressive effects of both types of medications could subsequently cause an increased risk, incidence, or severity of infections. In particular, the concomitant use of vedolizumab and TNF antagonists is not formally recommended because of the proposed possibility of increased and severe immunosuppression and risk of infection. In short, The risk or severity of infection can be increased when Adalimumab is combined with Vedolizumab, and the severity of the interaction is major.

Does Adalimumab and Vemurafenib interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vemurafenib can be increased when combined with Adalimumab, and the severity of the interaction is major.

Does Adalimumab and Venetoclax interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Venetoclax can be increased when combined with Adalimumab, and the severity of the interaction is major.

Does Adalimumab and Venlafaxine interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Venlafaxine can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Verapamil interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Verapamil can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Vernakalant interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Vernakalant can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Vibrio cholerae CVD 103-HgR strain live antigen interact?

High doses of immunosuppressive agents, such as antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids in combination with the cholera vaccine may reduce the immune response to the vaccine. In short, The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Adalimumab, and the severity of the interaction is minor.

Does Adalimumab and Vilanterol interact?

Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Vilanterol, and the severity of the interaction is major.

Does Adalimumab and Vilazodone interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Vilazodone can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Vinblastine interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vinblastine can be increased when combined with Adalimumab, and the severity of the interaction is major.

Does Adalimumab and Vincristine interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vincristine can be increased when combined with Adalimumab, and the severity of the interaction is major.

Does Adalimumab and Vindesine interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vindesine can be increased when combined with Adalimumab, and the severity of the interaction is major.

Does Adalimumab and Vinflunine interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vinflunine can be increased when combined with Adalimumab, and the severity of the interaction is major.

Does Adalimumab and Vinorelbine interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vinorelbine can be increased when combined with Adalimumab, and the severity of the interaction is major.

Does Adalimumab and Voclosporin interact?

Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Voclosporin, and the severity of the interaction is major.

Does Adalimumab and Vonoprazan interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Vonoprazan can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Vorapaxar interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Vorapaxar can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Voriconazole interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Voriconazole can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Vorinostat interact?

Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Vorinostat, and the severity of the interaction is major.

Does Adalimumab and Vortioxetine interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Vortioxetine can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Voxelotor interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Voxelotor can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Warfarin interact?

Prescribing information for adalimumab states that reduced cytokine activity from the use of adalimumab may influence the formation of cytochrome P450 enzymes. Cytokines have been shown to suppress CYP450 formation. When adalimumab is used, cytokine levels are normalized due to a decrease in inflammation. Warfarin is a substrate of the CYP450 enzymes, which may be induced by adalimumab indirectly via decreased levels of cytokines caused by adalimumab. This may lead to the increased metabolism and decreased serum concentration of warfarin, leading to subtherapeutic effects. Upon discontinuation of adalimumab, warfarin levels may increase, affecting INR and bleeding risk. In short, The serum concentration of Warfarin can be decreased when it is combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Yellow fever vaccine interact?

In a placebo-controlled clinical trial of patients with RA, no difference was detected in antipneumococcal antibody response between adalimumab and placebo treatment groups when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with adalimumab. Similar proportions of patients developed protective levels of anti-influenza antibodies between adalimumab and placebo treatment groups; however, titers in aggregate to influenza antigens were moderately lower in patients receiving adalimumab. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Yellow fever vaccine, and the severity of the interaction is minor.

Does Adalimumab and Yohimbine interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Yohimbine can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Zafirlukast interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Zafirlukast can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Zaleplon interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Zaleplon can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Zanubrutinib interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates with a narrow therapeutic index. In short, The metabolism of Zanubrutinib can be increased when combined with Adalimumab, and the severity of the interaction is major.

Does Adalimumab and Zidovudine interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Zidovudine can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Zileuton interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Zileuton can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Ziprasidone interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Ziprasidone can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Zolmitriptan interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Zolmitriptan can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Zolpidem interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Zolpidem can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Zonisamide interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Zonisamide can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Zopiclone interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Zopiclone can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Zuclopenthixol interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Zuclopenthixol can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Aducanumab and Abciximab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Adalimumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Alemtuzumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Alirocumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Alirocumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Amivantamab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Amivantamab, and the severity of the interaction is minor.

Does Aducanumab and Anifrolumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Anifrolumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Ansuvimab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Ansuvimab, and the severity of the interaction is minor.

Does Aducanumab and Anthrax immune globulin human interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Antilymphocyte immunoglobulin (horse) interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Antithymocyte immunoglobulin (rabbit) interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Asfotase alfa interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Atezolizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Atezolizumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Avelumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Avelumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Bamlanivimab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Bamlanivimab, and the severity of the interaction is minor.

Does Aducanumab and Basiliximab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Basiliximab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Belantamab mafodotin interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Belantamab mafodotin, and the severity of the interaction is minor.

Does Aducanumab and Belimumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Belimumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Benralizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Benralizumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Besilesomab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Besilesomab, and the severity of the interaction is minor.

Does Aducanumab and Bevacizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Bezlotoxumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Bezlotoxumab, and the severity of the interaction is minor.

Does Aducanumab and Bimekizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Bimekizumab, and the severity of the interaction is minor.

Does Aducanumab and Blinatumomab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Brentuximab vedotin interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Brodalumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Brodalumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Brolucizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Brolucizumab, and the severity of the interaction is minor.

Does Aducanumab and Burosumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Burosumab, and the severity of the interaction is minor.

Does Aducanumab and Canakinumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Canakinumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Caplacizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Caplacizumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Casirivimab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Casirivimab, and the severity of the interaction is minor.

Does Aducanumab and Cemiplimab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Cemiplimab, and the severity of the interaction is minor.

Does Aducanumab and Certolizumab pegol interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Cetuximab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Cetuximab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Conjugated estrogens interact?

Therapeutic immune globulins have been associated with the risk for adverse thromboembolic events, oftentimes leading to withdrawal from therapy. The use of estrogen-containing preparations, such as oral contraceptives (OC), is also a well established risk factor for venous thrombosis. Co-administration of two agents may further elevate the risk for developing thrombotic disorders. In short, Conjugated estrogens may increase the thrombogenic activities of Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Daratumumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Daratumumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Denosumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Denosumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Digoxin Immune Fab (Ovine) interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Dinutuximab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Dinutuximab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Dostarlimab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Dostarlimab, and the severity of the interaction is minor.

Does Aducanumab and Dulaglutide interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Dulaglutide is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Dupilumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Dupilumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Durvalumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Durvalumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Ebola Zaire vaccine (live, attenuated) interact?

Immunoglobulins suppress the immune response and may reduce the therapeutic effectiveness of live attenuated Ebola vaccine virus when co-administered in a short time frame, as vaccines work by eliciting an immune response. It is speculated that administration of immune globulins administered 3 months before or up to 1 month after the Ebola virus vaccine administration may interfere with the expected immune response. There is also a possibility of an infection, as live vaccines hold viral proteins and carry a risk of systemic infection, especially to individuals with profound immunosuppression caused by disease or drugs. In short, The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Eculizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Eculizumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Eflapegrastim interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Eflapegrastim, and the severity of the interaction is minor.

Does Aducanumab and Eftrenonacog alfa interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Elotuzumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Elotuzumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Emapalumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Emapalumab, and the severity of the interaction is minor.

Does Aducanumab and Emicizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Emicizumab, and the severity of the interaction is minor.

Does Aducanumab and Eptinezumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Eptinezumab, and the severity of the interaction is minor.

Does Aducanumab and Erenumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Erenumab, and the severity of the interaction is minor.

Does Aducanumab and Esterified estrogens interact?

Therapeutic immune globulins have been associated with the risk for adverse thromboembolic events, oftentimes leading to withdrawal from therapy. The use of estrogen-containing preparations, such as oral contraceptives (OC), is also a well established risk factor for venous thrombosis. Co-administration of two agents may further elevate the risk for developing thrombotic disorders. In short, Esterified estrogens may increase the thrombogenic activities of Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Estradiol acetate interact?

Therapeutic immune globulins have been associated with the risk for adverse thromboembolic events, oftentimes leading to withdrawal from therapy. The use of estrogen-containing preparations, such as oral contraceptives (OC), is also a well established risk factor for venous thrombosis. Co-administration of two agents may further elevate the risk for developing thrombotic disorders. In short, Estradiol acetate may increase the thrombogenic activities of Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Estradiol benzoate interact?

Therapeutic immune globulins have been associated with the risk for adverse thromboembolic events, oftentimes leading to withdrawal from therapy. The use of estrogen-containing preparations, such as oral contraceptives (OC), is also a well established risk factor for venous thrombosis. Co-administration of two agents may further elevate the risk for developing thrombotic disorders. In short, Estradiol benzoate may increase the thrombogenic activities of Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Estradiol cypionate interact?

Therapeutic immune globulins have been associated with the risk for adverse thromboembolic events, oftentimes leading to withdrawal from therapy. The use of estrogen-containing preparations, such as oral contraceptives (OC), is also a well established risk factor for venous thrombosis. Co-administration of two agents may further elevate the risk for developing thrombotic disorders. In short, Estradiol cypionate may increase the thrombogenic activities of Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Estradiol valerate interact?

Therapeutic immune globulins have been associated with the risk for adverse thromboembolic events, oftentimes leading to withdrawal from therapy. The use of estrogen-containing preparations, such as oral contraceptives (OC), is also a well established risk factor for venous thrombosis. Co-administration of two agents may further elevate the risk for developing thrombotic disorders. In short, Estradiol valerate may increase the thrombogenic activities of Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Estradiol interact?

Therapeutic immune globulins have been associated with the risk for adverse thromboembolic events, oftentimes leading to withdrawal from therapy. The use of estrogen-containing preparations, such as oral contraceptives (OC), is also a well established risk factor for venous thrombosis. Co-administration of two agents may further elevate the risk for developing thrombotic disorders. In short, Estradiol may increase the thrombogenic activities of Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Estriol interact?

Therapeutic immune globulins have been associated with the risk for adverse thromboembolic events, oftentimes leading to withdrawal from therapy. The use of estrogen-containing preparations, such as oral contraceptives (OC), is also a well established risk factor for venous thrombosis. Co-administration of two agents may further elevate the risk for developing thrombotic disorders. In short, Estriol may increase the thrombogenic activities of Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Estrone sulfate interact?

Therapeutic immune globulins have been associated with the risk for adverse thromboembolic events, oftentimes leading to withdrawal from therapy. The use of estrogen-containing preparations, such as oral contraceptives (OC), is also a well established risk factor for venous thrombosis. Co-administration of two agents may further elevate the risk for developing thrombotic disorders. In short, Estrone sulfate may increase the thrombogenic activities of Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Estrone interact?

Therapeutic immune globulins have been associated with the risk for adverse thromboembolic events, oftentimes leading to withdrawal from therapy. The use of estrogen-containing preparations, such as oral contraceptives (OC), is also a well established risk factor for venous thrombosis. Co-administration of two agents may further elevate the risk for developing thrombotic disorders. In short, Estrone may increase the thrombogenic activities of Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Ethinylestradiol interact?

Therapeutic immune globulins have been associated with the risk for adverse thromboembolic events, oftentimes leading to withdrawal from therapy. The use of estrogen-containing preparations, such as oral contraceptives (OC), is also a well established risk factor for venous thrombosis. Co-administration of two agents may further elevate the risk for developing thrombotic disorders. In short, Ethinylestradiol may increase the thrombogenic activities of Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Evolocumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Evolocumab is combined with Aducanumab, and the severity of the interaction is minor.

Does Aducanumab and Fremanezumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Aducanumab is combined with Fremanezumab, and the severity of the interaction is minor.